Debilitating Muscle Cramps after Teriparatide Therapy
Authors: Parul J. Kakaria, David J. Nashel, Eric S. Nylen
Journal: Annals of Internal Medicine (2005)

Letters15 February 2005Debilitating Muscle Cramps after Teriparatide TherapyParul J. Kakaria, MD, David J. Nashel, MD, and Eric S. Nylen, MDParul J. Kakaria, MDFrom George Washington University Hospital and Veterans Affairs Medical Center, Washington, DC., David J. Nashel, MDFrom George Washington University Hospital and Veterans Affairs Medical Center, Washington, DC., and Eric S. Nylen, MDFrom George Washington University Hospital and Veterans Affairs Medical Center, Washington, DC.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-142-4-200502150-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: Teriparatide, a recombinant human 1–34 amino acid sequence of parathyroid hormone, was recently approved in the United States for the treatment of men and postmenopausal women at high risk for osteoporotic fracture and in Europe for the treatment of postmenopausal women with osteoporosis. When given by once-daily injection, teriparatide increases bone mass by stimulating formation of new bone, resulting in the restoration of bone architecture (1). The adverse reactions that have been described are relatively mild. However, we observed a previously unreported reaction to teriparatide.Case Report: Teriparatide therapy was started in a 75-year-old woman with ...References1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41. [PMID: 11346808] CrossrefMedlineGoogle Scholar2. Clerx V, Van Den Keybus C, Kochuyt A, Goossens A. Drug intolerance reaction to insulin therapy caused by metacresol. Contact Dermatitis. 2003;48:162-3. [PMID: 12755733] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Parul J. Kakaria, MD; David J. Nashel, MD; Eric S. Nylen, MDAffiliations: From George Washington University Hospital and Veterans Affairs Medical Center, Washington, DC. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byUniversal Nature of Drug Treatment Responses in Drug-Tissue-Wide Model-Animal Experiments Using Tensor Decomposition-Based Unsupervised Feature ExtractionOsteoporosisTreatment of unresponsive hypoparathyroidism when the oral route administration is not possible: Considering subcutaneous teriparatideTreatment of unresponsive hypoparathyroidism when the oral route administration is not possible: Considering subcutaneous teriparatideMuscle cramps and weakness after teriparatide therapy: A new drug-induced myopathy?Current awareness: Pharmacoepidemiology and drug safetyPatient's Death Due to Another Case of Glycemic Control Problems with a Fluoroquinolone; Acute MI after OTC Pseudoephedrine Use; Asterixis Related to Gabapentin Results in Patient Falls; Antiseptic Bath Emollient Causes Acute Irritant Reaction to Genitalia; Peripheral Neuropathy with New Antifungal; Debilitating Muscle Cramps after Teriparatide Therapy Psychiatric Effects of Ephedra Use 15 February 2005Volume 142, Issue 4 Page: 310 Keywords Adverse reactions Bone Insulin Lower back pain Medical staff Muscles Osteoporosis Outpatient clinics Parathyroid hormone ePublished: 15 February 2005 Issue Published: 15 February 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...